ExonHit Therapeutics Inc. Announces Successful Completion of the Second Phase of EHT Dx14 Clinical Validation

Published: Jul 19, 2011

PARIS--(BUSINESS WIRE)--Regulatory News: Following the first data in benign and malignant fine-needle aspiration (FNA) samples communicated on March 29, Exonhit (Paris:ALEHT) today announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.

Back to news